Obsidian Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Obsidian Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Obsidian Therapeutics, Inc. Common Stock (OBX) has a cash flow conversion efficiency ratio of 0.080x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.01 Million) by net assets ($-276.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Obsidian Therapeutics, Inc. Common Stock (OBX) market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Obsidian Therapeutics, Inc. Common Stock (2024–2025)
Cash flow conversion efficiency of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how Obsidian Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Obsidian Therapeutics, Inc. Common Stock for real-time trading data and today's change.
Obsidian Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Obsidian Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Obsidian Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Obsidian Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Review how financially flexible is Obsidian Therapeutics, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
POSCO-Thainox Public Company Limited
BK:INOX
|
-0.040x |
|
Sumavision Technologies
SHE:300079
|
0.016x |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
0.046x |
|
Svenska Handelsbanken AB (publ)
ST:SHB-B
|
0.330x |
|
Rigol Technologies Co. Ltd. A
SHG:688337
|
N/A |
|
Dogan Sirketler Grubu Holding AS
IS:DOHOL
|
0.029x |
|
Develop Global Ltd
AU:DVP
|
0.042x |
|
Macquarie Technology Group Ltd
AU:MAQ
|
0.074x |
Annual Cash Flow Conversion Efficiency for Obsidian Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025. Also see Obsidian Therapeutics, Inc. Common Stock asset portfolio for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-266.04 Million | $-90.39 Million | 0.340x | -20.98% |
| 2024-12-31 | $-174.43 Million | $-75.00 Million | 0.430x | -- |
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform de… Read more